These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32259095)

  • 21. Suvorexant: The first orexin receptor antagonist to treat insomnia.
    Dubey AK; Handu SS; Mediratta PK
    J Pharmacol Pharmacother; 2015; 6(2):118-21. PubMed ID: 25969666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
    Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T
    Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
    Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
    Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
    [No Abstract]   [Full Text] [Related]  

  • 24. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 26. Suvorexant in insomnia: efficacy, safety and place in therapy.
    Rhyne DN; Anderson SL
    Ther Adv Drug Saf; 2015 Oct; 6(5):189-95. PubMed ID: 26478806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profile of suvorexant in the management of insomnia.
    Sutton EL
    Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.
    Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A
    Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies.
    Ten-Blanco M; Flores Á; Cristino L; Pereda-Pérez I; Berrendero F
    Front Neuroendocrinol; 2023 Apr; 69():101066. PubMed ID: 37015302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 35. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats.
    Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M
    J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.